Lilly, Boehringer launch Glyxambi; German watchdogs do a turnabout on Provenge;

@FiercePharma: ICYMI yesterday: Regeneron chief nabs $42M, but he'll have to pay his own club fees this year. Article | Follow @FiercePharma

@EricPFierce: ICYMI: When it comes to Big Pharma revenues, who's the biggest of them all? Special report | Follow @EricPFierce

@CarlyHFierce: GSK, U.K. 'hopeful' they can strike a Bexsero price deal soon. FierceVaccines story | Follow @CarlyHFierce

> Eli Lilly ($LLY) and Boehringer Ingelheim rolled out their combo diabetes drug Glyxambi--which melds the SGLT-2 drug Jardiance and the DPP-4 inhibitor Tradjenta--in the U.S. market. Release

> German cost watchdogs did an about-face on the Dendreon prostate cancer treatment Provenge, agreeing to back the drug after the company offered new cost-effectiveness data. Report

> Novo Nordisk ($NVO) won final European approval for its new obesity drug Saxenda, a reformulated version of its diabetes blockbuster Victoza; launches will begin later this year. Release

> Johnson & Johnson ($JNJ) prevailed in a patent fight over the ADHD med Concerta, when a judge knocked down claims from a doctor claiming to be a co-inventor of the drug. Report (reg. req.)

> Hungary's Richter will pay a dividend of 33 forints per share on 2014 earnings, down from 57 forints previously, the company said in its annual meeting announcement. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Foundation Medicine reveals C-suite and board metamorphosis. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Does the FDA overregulate devices? Experts weigh in. Report | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: French researchers harness wireless monitors to track drug-resistant bacteria. Story | Follow @EmilyWFierce

> Nearly 10,000 GE, Siemens MRI machines under FDA recall. Story

> Abiomed gains after FDA finally approves tiny heart pump. Report

> Startup raises Series A to launch interactive, holographic surgical imaging software. News

Biotech News

@FierceBiotech: Video: Is this a biotech bubble? Watch | Follow @FierceBiotech

@JohnCFierce: Daiichi Sankyo starts layoff drive with 16% cuts at HQ. FiercePharma report | Follow @JohnCFierce

@DamianFierce: We asked @FierceBiotech readers whether biotech is in a bubble or a sustainable boom. Here's what they said | Follow @DamianFierce

> Bristol, Sanofi and Novartis lead pack in big year for blockbusters. More

> Google's Calico widens its R&D net with QB3 partnership. Article

> Bristol-Myers picks up an autoimmune project as Novo quits the field. Report

Drug Delivery News

> Bacteria deliver molecule to gut to suppress hunger and ward off weight gain. Report

> Clearside's novel eye drug delivery tech shows promise in latest clinical trial. More

> 3D printing will enable creation of delivery devices on demand. Item

> Developer of men's health drug with novel delivery tech secures $1M+ in seed financing. Story

> Maker of microspheres for local delivery of radiation suffers clinical trial setback. Article

Pharma Manufacturing News

> India to invest in infrastructure that drugmakers can share. Item

> Deals for Actavis, Teva plants put G&W in the spotlight; CEO says its culture is its beacon. Editor's corner

> Cypriot company targets Vietnam for generic expansion. More

> Norway's Weifa bets growth on separate API biz. Story

> Chinese company balks on reopening Boehringer plant. Report

Pharma Asia News

> South Korea tells Bayer to divest oral contraceptives business. Report

> China FDA approves first proton carbon ion therapy for Siemens device. Item

> Sun winds up Ranbaxy deal. More

> Daiichi Sankyo starts layoff drive with 16% cuts at HQ. Article

> China FDA approves first proton carbon ion therapy for Siemens device. Item

And Finally... Drug-resistant tuberculosis could kill 75 million people by 2050, a new report says. Report